

# action

## ACCC Welcomes Its Newest Members

### **Baptist Health System**

Louisville, Ky.

Delegate Rep: Amanda Henson, MSHA, MBA, FACHE

Website: [baptisthealth.com](http://baptisthealth.com)

### **Baptist Health Paducah**

Paducah, Ky.

Delegate Rep: Michael Tutor, MBA

Website: [baptisthealth.com/Paducah](http://baptisthealth.com/Paducah)

### **System Membership**

#### **Munson Healthcare**

Traverse City, Mich.

Delegate Rep: Kathleen LaRaia, MS

Website: [munsonhealthcare.org/cancer](http://munsonhealthcare.org/cancer)

### **Scotland Memorial Hospital**

#### **Scotland Cancer Treatment Center**

Laurinburg, N.C.

Delegate Rep: Paula Love, RN, BSN, CLNC

Website: [scotlandhealth.org/medical-services/cancer-center-duke-health-affiliate](http://scotlandhealth.org/medical-services/cancer-center-duke-health-affiliate)

### **Utah Cancer Specialists**

Salt Lake City, Utah

Delegate Rep: Amy Pasmann, MS, RN

Website: [utahcancer.com](http://utahcancer.com)

## A Reminder from ACCC's Bylaws Committee

Dec. 1 is the deadline for submission of any proposed amendments to the ACCC Bylaws. Proposed recommendations should be sent to Betsy Spruill at [bspruill@acc-cancer.org](mailto:bspruill@acc-cancer.org). ACCC's Bylaws are available online at [acc-cancer.org/bylaws](http://acc-cancer.org/bylaws).

## ACCC Research Review

This monthly e-newsletter is part of the 2020-2021 ACCC President's Theme, "Community Oncology Can Close the Gap in Cancer Research." In addition to updates from the President's task force, each issue will focus on:

- Clinical trials of interest to ACCC members, such as the recent Ochsner Health study published in the *New England Journal of Medicine* titled "Hospitalization and Mortality Among Black Patients and White Patients with Covid-19"
- Feature articles like "All Power to the Patient: Achieving Cancer Health Equity" with five key takeaway messages from this U.S. Food and Drug Administration Oncology Center of Excellence webinar
- Key insights from ACCC members in specific areas of research like precision medicine and oncogeriatrics.

If you missed this new e-newsletter, start with the inaugural issue at [acc-cancer.org/research-newsletter-july-2020](http://acc-cancer.org/research-newsletter-july-2020) and then catch up. Do you know someone in your research department who should be getting this important resource? Sign them up to receive this e-newsletter and other research-related updates at the link above.



**ACCC Research Review**  
HELPING COMMUNITY ONCOLOGY TO  
CLOSE THE GAP IN CANCER RESEARCH

## ACCC Releases New IO Resources

Recent advances in immuno-oncology (IO) therapies have been rewarded by rapid, durable responses for subsets of patients in many cancers that have been resistant to conventional treatments. Just as with developments with chemotherapy and targeted therapies, increasing numbers of IO patients with metastatic disease are transitioning into post-treatment survivorship. However, these patients may experience late physical and psychosocial effects of cancer and its treatment (e.g., depression, pain, fatigue), which can negatively impact quality of life.

In this ACCC video series, expert panels discuss the unique survivorship needs of IO patients, including improving care coordination and communication within the multidisciplinary team and how to meet patients' psychosocial and physical well-being needs. These discussions identify actionable steps for cancer care providers and allied healthcare professionals to address the survivorship needs of this patient population. Watch today at [accancer.org/io-survivorship-webinars](https://accancer.org/io-survivorship-webinars).

## New Collaboration Seeks to Increase Clinical Trial Participation of Racial and Ethnic Minority Populations

In July ACCC and the American Society of Clinical Oncology (ASCO) announced a new collaboration to foster participation in cancer treatment trials to better reflect the diversity of people at risk for or living with cancer.

“We recognize that there are complex forces and systems that have created disparities in cancer research and that solving these problems will take a multi-faceted integrated approach reflecting the best current thinking and expertise from the entire cancer community,” said ACCC President Randall A. Oyer, MD, co-chair of the new ASCO-ACCC steering group overseeing this initiative.

That same month, the two organizations released the ASCO-ACCC Request for Ideas, which closed at the end of August, seeking novel strategies and practical solutions to increase participation of under-represented racial and ethnic populations in cancer treatment trials. Request for Ideas' areas of focus included:

- Provider bias
- Challenges with access, insurance coverage, and cost of care
- Lack of awareness about trials
- Mistrust in the healthcare system and/or clinical research
- Linguistic, cultural, or literacy-related issues
- Study design barriers
- Barriers to family and community engagement.

The ASCO-ACCC steering group will review and select ideas that may be modified, combined, implemented, and evaluated by the two organizations. Submitted ideas may be implemented and evaluated through the ASCO Targeted Agent and Profiling Utilization Registry Study, for example.

Criteria used to review and prioritize proposed ideas will include the potential to address racial and ethnic disparities in cancer treatment trials, replicability of the strategy, and indications that the submitter has demonstrated a commitment to equitable cancer care, among others. Individuals who submit ideas will be given an opportunity to work on the idea implementation, if interested.